甲状腺がん(Thyroid Cancer):治療薬開発パイプライン動向(2014年下半期版)

◆英語タイトル:Thyroid Cancer - Pipeline Review, H2 2014
◆商品コード:GMDHC5800IDB
◆発行会社(リサーチ会社):Global Markets Direct
◆発行日:2014年11月30日
◆ページ数:110
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆調査対象地域:グローバル
◆販売価格オプション(消費税別)
Single UserUSD2,000 ⇒換算¥208,000見積依頼/購入/質問フォーム
Site License(同一国内共有可)USD4,000 ⇒換算¥416,000見積依頼/購入/質問フォーム
Global Site License(複数国内共有可)USD6,000 ⇒換算¥624,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobal Markets Direct社の日本における正規販売代理店です。同社発行の医療分野調査レポートに関するお問い合わせは弊社までお願い致します。
Global Markets Direct社の概要はこちらでご確認いただけます。
※上記「見積依頼/購入/質問フォーム」をクリックすると弊社運営のレポート販売サイトに移動します。

当調査レポートでは、世界における甲状腺がん(Thyroid Cancer)の治療薬開発パイプライン動向について調査・分析し、企業で開発中の治療薬、大学/研究機関で研究中の治療薬、後期段階の製品、治験段階の製品、初期段階の製品、単剤治療薬/併用治療薬/標的別/作用機序別/投与経路別/分子の種類別治療薬の評価、各薬剤のプロファイル(説明、作用機序、研究開発の進展状況)などのデータをお届けいたします。

・イントロダクション
・甲状腺がん(Thyroid Cancer)の概要
・甲状腺がん(Thyroid Cancer)治療薬の開発
  - パイプライン製品の概要
  - パイプライン製品の比較分析
・企業で開発中の治療薬
・大学/研究機関で研究中の治療薬
・甲状腺がん(Thyroid Cancer)パイプライン製品の概略
  - 後期段階の製品
  - 治験段階の製品
  - 初期段階の製品
・製品
・大学/研究機関別、研究中の製品
・甲状腺がん(Thyroid Cancer)治療薬開発に取り組んでいる企業:企業別製品パイプライン
・甲状腺がん(Thyroid Cancer)治療薬の評価
  - 単剤治療薬
  - 併用治療薬
  - 標的別
  - 作用機序(MoA)別
  - 投与経路(RoA)別
  - 分子の種類別
・各薬剤のプロファイル:説明、作用機序、研究開発(R&D)の進展状況
・パイプライン製品の最新動向
・開発休止中の製品/プロジェクト
・開発が中止された製品
・製品開発のマイルストーン
【レポートの概要】

Thyroid Cancer – Pipeline Review, H2 2014

Summary

Global Markets Direct’s, ‘Thyroid Cancer – Pipeline Review, H2 2014’, provides an overview of the Thyroid Cancer’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Thyroid Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Thyroid Cancer and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Thyroid Cancer
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Thyroid Cancer and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Thyroid Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Thyroid Cancer pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Thyroid Cancer
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Thyroid Cancer pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

【レポートの目次】

Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 6
Introduction 7
Global Markets Direct Report Coverage 7
Thyroid Cancer Overview 8
Therapeutics Development 9
Pipeline Products for Thyroid Cancer – Overview 9
Pipeline Products for Thyroid Cancer – Comparative Analysis 10
Thyroid Cancer – Therapeutics under Development by Companies 11
Thyroid Cancer – Therapeutics under Investigation by Universities/Institutes 13
Thyroid Cancer – Pipeline Products Glance 14
Late Stage Products 14
Clinical Stage Products 15
Early Stage Products 16
Thyroid Cancer – Products under Development by Companies 17
Thyroid Cancer – Products under Investigation by Universities/Institutes 18
Thyroid Cancer – Companies Involved in Therapeutics Development 19
AstraZeneca PLC 19
Azaya Therapeutics Incorporated 20
Bio-Path Holdings, Inc. 21
Biovista Inc. 22
centrose llc 23
Ecrins Therapeutics SAS 24
Eisai Co., Ltd. 25
GlaxoSmithKline plc 26
Novartis AG 27
Translational Therapeutics, Inc. 28
Trophogen, Inc. 29
Vascular Biogenics Ltd. 30
Thyroid Cancer – Therapeutics Assessment 31
Assessment by Monotherapy Products 31
Assessment by Target 32
Assessment by Mechanism of Action 35
Assessment by Route of Administration 37
Assessment by Molecule Type 39
Drug Profiles 41
BP-100-1.02 – Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
BVA-501 – Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
BVA-701 – Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
docetaxel liposomal – Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
EDC-1 – Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
ETD-5 – Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
everolimus – Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
Gene Therapy to Activate p53 for Oncology – Drug Profile 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
GSK-2256098 – Drug Profile 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
lenvatinib – Drug Profile 56
Product Description 56
Mechanism of Action 56
R&D Progress 56
MVX-ONCO-1 – Drug Profile 60
Product Description 60
Mechanism of Action 60
R&D Progress 60
panobinostat – Drug Profile 61
Product Description 61
Mechanism of Action 61
R&D Progress 61
pazopanib hydrochloride – Drug Profile 67
Product Description 67
Mechanism of Action 67
R&D Progress 67
Recombinant Protein to Agonize VEGF for Thyroid and Multiple Other Cancers – Drug Profile 72
Product Description 72
Mechanism of Action 72
R&D Progress 72
selumetinib sulfate – Drug Profile 73
Product Description 73
Mechanism of Action 73
R&D Progress 73
Small Molecules to Antagonize ALK for Oncology – Drug Profile 76
Product Description 76
Mechanism of Action 76
R&D Progress 76
Small Molecules to Inhibit PAK for Thyroid Cancer – Drug Profile 77
Product Description 77
Mechanism of Action 77
R&D Progress 77
TR-1401 – Drug Profile 78
Product Description 78
Mechanism of Action 78
R&D Progress 78
TRX-201 – Drug Profile 79
Product Description 79
Mechanism of Action 79
R&D Progress 79
VB-111 – Drug Profile 80
Product Description 80
Mechanism of Action 80
R&D Progress 80
Thyroid Cancer – Recent Pipeline Updates 81
Thyroid Cancer – Dormant Projects 98
Thyroid Cancer – Discontinued Products 99
Thyroid Cancer – Product Development Milestones 100
Featured News & Press Releases 100
Nov 26, 2014: Eisai Opens Multi-million Pound High Tech Global Potent Packaging Facility For New Cancer Treatment in Hatfield, UK 100
Oct 14, 2014: U.S. FDA Grants Eisai’s Investigational Agent Lenvatinib Priority Review Designation for the Treatment of Advanced Thyroid Cancer 101
Sep 17, 2014: Eisai to Present Clinical Data on Lenvatinib at 39th ESMO Congress 102
Sep 06, 2014: Significant Improvement in Progression-Free Survival With Lenvatinib in Radioiodine-Refractory Differentiated Thyroid Cancer: Data Confirmed in New Subgroup Analyses 103
Aug 18, 2014: Eisai submits Marketing Approval Application for Anti cancer Agent Lenvatinib Simultaneously in Europe And U.S. 104
Jul 31, 2014: Ema Accepts Eisai’s Request For Accelerated Assessment Of Anticancer Agent Lenvatinib 105
Jun 26, 2014: Eisai Submits First Marketing Authorization Application for Anticancer agent Lenvatinib in Japan 105
May 31, 2014: Lenvatinib Phase III Results Show Significant Improvement In Progression-Free Survival In Patients With Radioiodine-Refractory Differentiated Thyroid Cancer 106
May 15, 2014: Eisai to Present Abstracts On Lenvatinib At 50th ASCO Annual Meeting 107
Feb 03, 2014: Phase III Trial Shows Lenvatinib Meets Primary Endpoint Of Progression Free Survival Benefit in Treatment Of Radioiodine-refractory Differentiated Thyroid Cancer 108
Appendix 109
Methodology 109
Coverage 109
Secondary Research 109
Primary Research 109
Expert Panel Validation 109
Contact Us 110
Disclaimer 110

[List of Tables]
Number of Products under Development for Thyroid Cancer, H2 2014 9
Number of Products under Development for Thyroid Cancer - Comparative Analysis, H2 2014 10
Number of Products under Development by Companies, H2 2014 12
Number of Products under Investigation by Universities/Institutes, H2 2014 13
Comparative Analysis by Late Stage Development, H2 2014 14
Comparative Analysis by Clinical Stage Development, H2 2014 15
Comparative Analysis by Early Stage Development, H2 2014 16
Products under Development by Companies, H2 2014 17
Products under Investigation by Universities/Institutes, H2 2014 18
Thyroid Cancer - Pipeline by AstraZeneca PLC, H2 2014 19
Thyroid Cancer - Pipeline by Azaya Therapeutics Incorporated, H2 2014 20
Thyroid Cancer - Pipeline by Bio-Path Holdings, Inc., H2 2014 21
Thyroid Cancer - Pipeline by Biovista Inc., H2 2014 22
Thyroid Cancer - Pipeline by centrose llc, H2 2014 23
Thyroid Cancer - Pipeline by Ecrins Therapeutics SAS, H2 2014 24
Thyroid Cancer - Pipeline by Eisai Co., Ltd., H2 2014 25
Thyroid Cancer - Pipeline by GlaxoSmithKline plc, H2 2014 26
Thyroid Cancer - Pipeline by Novartis AG, H2 2014 27
Thyroid Cancer - Pipeline by Translational Therapeutics, Inc., H2 2014 28
Thyroid Cancer - Pipeline by Trophogen, Inc., H2 2014 29
Thyroid Cancer - Pipeline by Vascular Biogenics Ltd., H2 2014 30
Assessment by Monotherapy Products, H2 2014 31
Number of Products by Stage and Target, H2 2014 33
Number of Products by Stage and Mechanism of Action, H2 2014 36
Number of Products by Stage and Route of Administration, H2 2014 38
Number of Products by Stage and Molecule Type, H2 2014 40
Thyroid Cancer Therapeutics - Recent Pipeline Updates, H2 2014 81
Thyroid Cancer - Dormant Projects, H2 2014 98
Thyroid Cancer - Discontinued Products, H2 2014 99

[List of Figures]
Number of Products under Development for Thyroid Cancer, H2 2014 9
Number of Products under Development for Thyroid Cancer - Comparative Analysis, H2 2014 10
Number of Products under Development by Companies, H2 2014 11
Number of Products under Investigation by Universities/Institutes, H2 2014 13
Comparative Analysis by Late Stage Development, H2 2014 14
Comparative Analysis by Clinical Stage Development, H2 2014 15
Comparative Analysis by Early Stage Products, H2 2014 16
Assessment by Monotherapy Products, H2 2014 31
Number of Products by Top 10 Targets, H2 2014 32
Number of Products by Stage and Top 10 Targets, H2 2014 32
Number of Products by Top 10 Mechanism of Actions, H2 2014 35
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2014 35
Number of Products by Top 10 Routes of Administration, H2 2014 37
Number of Products by Stage and Top 10 Routes of Administration, H2 2014 38
Number of Products by Top 10 Molecule Types, H2 2014 39
Number of Products by Stage and Top 10 Molecule Types, H2 2014 40

【掲載企業】

AstraZeneca PLC
Azaya Therapeutics Incorporated
Bio-Path Holdings, Inc.
Biovista Inc.
centrose llc
Ecrins Therapeutics SAS
Eisai Co., Ltd.
GlaxoSmithKline plc
Novartis AG
Translational Therapeutics, Inc.
Trophogen, Inc.
Vascular Biogenics Ltd.

【免責事項】
https://www.marketreport.jp/reports-disclaimer

★医療情報レポート[甲状腺がん(Thyroid Cancer):治療薬開発パイプライン動向(2014年下半期版)]についてメールでお問い合わせはこちら



◆H&Iグローバルリサーチ株式会社のお客様(例)◆